Cargando…

Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease

Background. Despite enzyme replacement therapy, Fabry nephropathy still progresses. Podocyturia is an irreversible event that antedates proteinuria and leads to chronic renal failure. We evaluated a potential mechanism of podocyte detachment via the expression of the urokinase-type Plasminogen Activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trimarchi, Hernán, Canzonieri, Romina, Schiel, Amalia, Politei, Juan, Costales-Collaguazo, Cristian, Stern, Aníbal, Paulero, Matías, Rengel, Tatiana, Valiño-Rivas, Lara, Forrester, Mariano, Lombi, Fernando, Pomeranz, Vanesa, Iriarte, Romina, Muryan, Alexis, Ortiz, Alberto, Sanchez-Niño, María Dolores, Zotta, Elsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420917/ https://www.ncbi.nlm.nih.gov/pubmed/28523190 http://dx.doi.org/10.1155/2017/1287289

Ejemplares similares

Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes
por: Trimarchi, Hernán, et al.
Publicado: (2018)

In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Increased urinary CD80 excretion and podocyturia in Fabry disease
por: Trimarchi, H., et al.
Publicado: (2016)

In Acute IgA Nephropathy, Proteinuria and Creatinine Are in the Spot, but Podocyturia Operates in Silence: Any Place for Amiloride?
por: Trimarchi, H., et al.
Publicado: (2017)

Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
por: Trimarchi, H., et al.
Publicado: (2016)

Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease
por: Trimarchi, H., et al.
Publicado: (2015)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR
por: Trimarchi, H., et al.
Publicado: (2014)

Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis
por: Trimarchi, Hernán, et al.
Publicado: (2011)

Mucin-1 Gene Mutation and the Kidney: The Link between Autosomal Dominant Tubulointerstitial Kidney Disease and Focal and Segmental Glomerulosclerosis
por: Trimarchi, H., et al.
Publicado: (2018)

Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?
por: Trimarchi, Hernán, et al.
Publicado: (2012)

Initially Nondiagnosed Fabry's Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis
por: Trimarchi, H., et al.
Publicado: (2013)

Proteinuria and its relation to diverse biomarkers and body mass index in chronic hemodialysis
por: Trimarchi, Hernán, et al.
Publicado: (2013)

Proteinuria, (99m)Tc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease
por: Trimarchi, Hernán, et al.
Publicado: (2014)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
por: Mauer, Michael, et al.
Publicado: (2014)

Parenteral Succinate Reduces Systemic ROS Production in Septic Rats, but It Does Not Reduce Creatinine Levels
por: Chapela, Sebastián P., et al.
Publicado: (2018)

1,25-Dihydroxyvitamin D(3) Inhibits Podocyte uPAR Expression and Reduces Proteinuria
por: Ma, Jianchao, et al.
Publicado: (2013)

Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
por: Liebau, Max C., et al.
Publicado: (2013)

Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued
por: Politei, Juan
Publicado: (2020)

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
por: Fall, Brent, et al.
Publicado: (2016)

Fibrosis: a key feature of Fabry disease with potential therapeutic implications
por: Weidemann, Frank, et al.
Publicado: (2013)

Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
por: Braun, Fabian, et al.
Publicado: (2023)

Non-canonical NFκB activation promotes chemokine expression in podocytes
por: Valiño-Rivas, Lara, et al.
Publicado: (2016)

Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes
por: Cuarental, Leticia, et al.
Publicado: (2020)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
por: Prabakaran, Thaneas, et al.
Publicado: (2011)

Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease
por: Hamed, Alaa, et al.
Publicado: (2021)

Hypertrophy of unaffected cardiomyocytes correlates with severity of cardiomyopathy in female patients with Fabry disease
por: Chimenti, Cristina, et al.
Publicado: (2021)

MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes
por: Lang, Yue, et al.
Publicado: (2019)

Fabry disease and COVID-19: International expert recommendations for management based on real-world experience
por: Laney, Dawn A., et al.
Publicado: (2021)

Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
por: Laney, Dawn A, et al.
Publicado: (2020)

Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2018)

Prevalence of Fabry disease in male dialysis patients: Argentinean screening study
por: Frabasil, Joaquín, et al.
Publicado: (2019)

Prevalence of papillary muscle hypertrophy in fabry disease
por: Cianciulli, Tomás Francisco, et al.
Publicado: (2023)

Hypertrophic obstructive cardiomyopathy caused by Fabry disease: implications for surgical myectomy
por: Frustaci, Andrea, et al.
Publicado: (2023)

Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies
por: Thurberg, Beth L., et al.
Publicado: (2016)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
por: Serebrinsky, G., et al.
Publicado: (2015)

Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey
por: Morand, Olivier, et al.
Publicado: (2019)

Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease
por: Carmona, Sergio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1v1jg963lnnvoqt2uq0pmi80bc